Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343532 · ClinicalTrials.gov registry record · Phase 1
SXC-2023 Cocaine Interaction Study
A Phase 1 study of Cocaine Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT06343532 is a Phase 1 study of Cocaine Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 17 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06343532, a Phase 1 study of Cocaine Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.
Conditions Studied
Interventions
- DRUG SXC-2023
- DRUG SXC-2023 Placebo
Study Locations (1)
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06343532
The ClinicalTrials.gov registry entry for NCT06343532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (83% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which SXC-2023 is the first listed.
NCT06343532 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT06343532 about?
NCT06343532 is a clinical study titled "SXC-2023 Cocaine Interaction Study". The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.
What is the current status of trial NCT06343532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-11. Estimated completion is 2024-12-30.
What conditions does trial NCT06343532 study?
This clinical trial studies the following conditions: Cocaine Use Disorder.
What interventions are being tested in trial NCT06343532?
The interventions under investigation include: SXC-2023 (DRUG), SXC-2023 Placebo (DRUG).
Who is sponsoring clinical trial NCT06343532?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06343532 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reinforcing Effects of Cocaine During Phendimetrazine Maintenance
COMPLETED · Phase 1
-
Cocaine Opioid Oxytocin Option - Limited
COMPLETED · Phase 1
-
The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)
COMPLETED · Phase 1
-
Phase1, STP7 Cocaine Drug-Drug Interaction Study
COMPLETED · Phase 1
-
Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder
COMPLETED · Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.